Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

739
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
739
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

528
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
528
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

526
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
526
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

392
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
392
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

729
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
729
Depression: Overview01:18

Depression: Overview

721
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
721

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between ASPECTS regions and clinical outcomes following endovascular therapy in patients with large infarcts: a post hoc analysis of the ANGEL-ASPECT trial.

Stroke and vascular neurology·2026
Same author

Frailty in older maintenance hemodialysis patients: A latent class analysis revealing personalized management.

PloS one·2026
Same author

TWGFD: an integrative platform for tetraploid wheat gene family analysis.

BMC genomics·2026
Same author

Combined multiphase CTA and CTP in assessing cerebral collateral circulation and predicting prognosis in AIS/TIA with symptomatic MCA M1 stenosis/occlusion: a subacute, non-reperfused cohort.

Neuroradiology·2026
Same author

Phytochemical-based quality and marker identification of sweet tea (<i>Lithocarpus litseifolius</i> [hance] Chun) from various Jiangxi regions.

Food chemistry: X·2026
Same author

AI Chatbot Suicide Risk Detection and Response: Human Validation Study of the Open-Source VERA-MH Safety Evaluation.

JMIR AI·2026

Related Experiment Video

Updated: Jan 3, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:36

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

196

Treating depressive disorders with the Unified Protocol: A preliminary randomized evaluation.

Shannon Sauer-Zavala1, Kate H Bentley2, Stephanie Jarvi Steele3

  • 1Department of Psychology, University of Kentucky, Lexington, KY, U.S.A.

Journal of Affective Disorders
|November 25, 2019
PubMed
Summary

The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) effectively reduced depressive symptoms in adults with depressive disorders. This transdiagnostic approach showed lasting benefits at 12-month follow-up.

Keywords:
DepressionTransdiagnostic treatmentUnified Protocol

More Related Videos

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

18.4K
An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

23.3K

Related Experiment Videos

Last Updated: Jan 3, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:36

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

196
The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

18.4K
An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

23.3K

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Emotional Disorders

Background:

  • Depressive disorders are a significant public health concern.
  • Transdiagnostic treatments offer a promising avenue for addressing emotional disorders.
  • The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) has shown efficacy for anxiety disorders.

Purpose of the Study:

  • To investigate the efficacy of the UP for individuals diagnosed with a depressive disorder.
  • To evaluate the UP's effectiveness in reducing depressive symptoms.
  • To assess the long-term effects of the UP on depression.

Main Methods:

  • 44 adults with major depressive disorder, persistent depressive disorder, or specified depressive disorder were included.
  • Participants were part of a larger clinical trial comparing the UP to single-disorder protocols and a waitlist control.
  • Depressive symptoms were assessed using clinician-rated and self-report measures at baseline, post-treatment, and 12-month follow-up.

Main Results:

  • Significant reductions in depressive symptoms were observed in the UP group from baseline to 12-month follow-up.
  • The UP group showed significantly lower depressive symptoms compared to the waitlist control at post-treatment.
  • No significant differences in depressive symptoms were found between the UP and single-disorder protocols at post-treatment or follow-up.

Conclusions:

  • The UP demonstrated efficacy in reducing depressive symptoms in individuals with depressive disorders.
  • These findings support the utility of the UP as a transdiagnostic treatment for depression.
  • Further research is warranted to explore the UP's application across a broader range of emotional disorders.